Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 11 Show results per page	View Search Criteria \| Help With Results

Last Modified: 1/1/2000 First Published: 8/1/1999


1.		Phase III Randomized Study of Hematologic Parameters to Maximize CD34+ Harvest and Initiate Leukapheresis Following Peripheral Blood Stem Cell Mobilization With Cyclophosphamide, Paclitaxel, Filgrastim (G-CSF), and Stem Cell Factor in Patients With Stage II, III, or IV Breast Cancer (Summary Last Modified 01/2000)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				NCI, Pharmaceutical / Industry				CWRU-AMGN-1198 AMGEN-SCF-980165, NCI-G99-1547

Last Modified: 11/1/1994


2.		Phase I/II Study of Peripheral Blood Progenitor Cell (PBPC) Mobilization in Response to Human Stem Cell Factor +/- G-CSF and of the Efficacy of PBPC plus G-CSF as a Rescue Regimen Following Myeloablative Chemotherapy in High-Risk Stage II and Stage III/IV Breast Cancer (Summary Last Modified 11/94)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Completed				18 to 62								UCLA-HSPC-9303106 NCI-V94-0503

Last Modified: 10/1/1993


3.		Phase I/II Randomized Study of PBPC Mobilized with r-metHuSCF and/or G-CSF in Patients with Intermediate- or Immunoblastic High-Grade non-Hodgkin's Lymphoma (Summary Last Modified 10/93)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Completed				18 to 65								MSKCC-93060 NCI-V93-0270

Last Modified: 8/1/1997


4.		Phase II Randomized Study of Stem Cell Factor vs G-CSF for Mobilization of Peripheral Blood Progenitor Cells in Heavily Pretreated Patients with non-Hodgkin's Lymphoma or Hodgkin's Disease (Summary Last Modified 08/97)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 to 65				Pharmaceutical / Industry				AMGEN-SCF-950123 NCI-V96-0956

Last Modified: 10/1/1998


5.		Randomized Phase II Study of Filgrastim and Stem Cell Factor (r-metHuSCF) in Priming of Bone Marrow for Autologous Transplantation in Patients with Relapsed or Refractory Hodgkin's Disease (HD) or Non-Hodgkin's Lymphoma (NHL) (Summary Last Modified 10/98)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI				RPCI-DS-96-24 NCI-G97-1153

Last Modified: 11/1/2000 First Published: 8/1/1999


6.		Phase II Study of Sequential High Dose Chemotherapy With Cyclophosphamide and Paclitaxel, Mitoxantrone and Cytarabine, and Etoposide and Melphalan Plus Autologous Peripheral Blood Stem Cell Transplantation in Patients With Chemotherapy Sensitive Relapsed Non-Hodgkin's Lymphoma (Summary Last Modified 11/2000)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI				FCCC-98052 NCI-G99-1541, NCT00003957

Last Modified: 11/13/2007


7.		Phase II Pilot Study of High-Dose Ifosfamide/Carboplatin/Etoposide (ICE) Followed by Transplantation with neo-r-Transduced Autologous Bone Marrow and PBSC for Metastatic Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 to 60				NCI				NCI-92-C-0161I NCI-MB-294, NCI-T92-0018N, T92-0018

Last Modified: 11/7/2007


8.		Phase II Study of High-Dose L-PAM and TBI with Autologous Bone Marrow and PBSC Support Followed by IFN-A for Multiple Myeloma, with Genetic Marking with Retroviral Vectors to Study the Feasibility of Stem Cell Gene Transfer and the Biology of Hematologic Reconstitution

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				up to 65				NHLBI				NHLBI-92-H-57 NCI-T92-0139N, T92-0139

Last Modified: 8/1/2000


9.		Phase I Pilot Study of Sequential High-Dose Chemotherapy for Stage IV Breast Cancer: Methotrexate/Fluorouracil/Leucovorin, Cyclophosphamide, Thiotepa with Peripheral Blood Stem Cell Rescue (with MDR1 and NeoR Gene Transduction of Cells), Paclitaxel, and Doxorubicin (Summary Last Modified 08/2000)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Completed				18 and over				NCI				NCI-96-C-0007K NCI-MB-361, NCI-T95-0096N, T95-0096

Last Modified: 11/1/2000 First Published: 7/1/2000


10.		Phase I Study of Interleukin-2 and Stem Cell Factor Following Autologous Peripheral Blood Stem Cell Transplantation in Patients With Non-Hodgkin's Lymphoma, Hodgkin's Disease, or Advanced Breast Cancer (Summary Last Modified 11/2000)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Closed				18 to 65				NCI				UMN-MT-9821 NCI-G00-1803, NCT00005993

Select All on One Page


					1 2 Next >

| | | | | | | |

A Service of the National Cancer Institute